CSL Ltd Annual Report 2019

110 Megan Clark AC BSc (Hons) PhD Age 61 Independent Non- executive Director Dr Megan Clark AC has been a Director of CSL Limited since February 2016. Dr Clark has significant executive and non-executive experience across a broad range of sectors including scientific research, health, investment banking and financial services, education and mining. Through her roles, Dr Clark brings a broad strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance. Dr Clark was Chief Executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 until November 2014. Prior to joining CSIRO, she was a Director at NM Rothschild and Sons (Australia) and held senior positions at BHP, including Vice President Technology and Vice President Health, Safety and Environment. Other directorships and offices (current and recent): –– Director of Rio Tinto Limited and Rio Tinto Plc (since November 2014); –– Director of Care Australia Limited (since May 2015); –– Member of the Australian advisory board of the Bank of America Merrill Lynch (since July 2010); –– Member of Council of Monash University Council (since April 2015); and –– Head of the Australian Space Agency (since June 2018). Board Committee Memberships: –– Chairman of the Human Resources and Remuneration Committee. –– Member of the Corporate Governance and Nomination Committee. –– Member of the Innovation and Development Committee. Abbas Hussain BSc (Hons) Age 54 Independent Non- executive Director Mr Abbas Hussain has been a Director of CSL Limited since February 2018. Mr Hussain has executive experience in the biopharmaceutical industry and deep biotechnology industry insight. Through his executive and non-executive roles, Mr Hussain has a broad global perspective and understanding of pharmaceutical manufacturing, product development, risk, health, safety, environment and corporate responsibility. Mr Hussain was the Global President, Pharmaceutical at GlaxoSmithKline (GSK) serving from 2008 to late 2017, where he managed a global pharmaceutical and vaccine business across 150 markets including the US, Europe, Japan and emerging markets. Before GSK he held senior roles with global responsibilities at Eli Lilly. Other directorships and offices (current and recent): –– Director of Immunocore Limited (since May 2017); –– Director of Cochlear Limited (since December 2018); –– Senior Advisor on the Advisory Board of CellResearch Corporation (since August 2017); –– Senior Advisor at C-Bridge Capital (since October 2017); and –– Former Director of ViiV Healthcare Limited (fromOctober 2009 to July 2017). Board Committee membership: –– Member of the Innovation and Development Committee. –– Member of the Human Resources and Remuneration Committee. Marie McDonald BSc (Hons), LLB (Hons) Age 63 Independent Non- executive Director Ms. Marie McDonald has been a Director of CSL Limited since August 2013 Ms McDonald has significant executive and non-executive experience in a number of sectors including law, medical research, manufacturing and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance and change management. Ms McDonald is a former lawyer with over 30 years’ experience in the legal sector. She was previously a partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She held the role of National Head of Mergers and Acquisitions and was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia and a Member of the Australian Takeovers Panel for nine years. Other directorships and offices (current and recent): –– Director of Nanosonics Limited (since October 2016); –– Director of Nufarm Limited (since March 2017); and –– Director of the Walter & Eliza Hall Institute of Medical Research (since October 2016). Board Committee membership: –– Member of the Audit and Risk Management Committee. –– Member of the Human Resources and Remuneration Committee. CSL Limited Annual Report 2019 44 Governance